Dental Management of the Hypertensive Patient

Table of Contents

Epidemiology and the dental screening role
Classifications: ESC 2024 and AHA/ACC 2025
Screening methodology and BP measurement
Clinical decision thresholds for dental procedures
Stress physiology and sedation protocols
Local anaesthesia and vasoconstrictors
Drug interactions with antihypertensives
Complex procedures in the hypertensive patient
Emergency management of hypertensive crises
Associated cardiovascular pathology and IE

Epidemiology and the Strategic Role of the Dental Practice

Arterial hypertension (AHT) represents one of the most prevalent chronic cardiovascular conditions worldwide. Often described as the "silent killer", it remains asymptomatic for prolonged periods, considerably delaying clinical diagnosis. In the United States, recent epidemiological data indicate that approximately 120 million adults — nearly half the adult population — are affected. Among them, an estimated 78% present uncontrolled hypertension, and 35.3% of hypertensive adults are entirely unaware of their condition.

The Dental Chair as a Screening Gateway

Approximately 29 million individuals consult a dentist annually without seeing a general practitioner or cardiologist. The literature confirms that nearly one in four hypertensive patients is identified for the very first time during a routine dental visit. The dental surgeon is no longer merely an orofacial specialist but a frontline actor in the preventive diagnosis of systemic disease.

The pathophysiological relationship between oral health and cardiovascular health is bidirectional and extensively documented. Periodontal diseases, affecting over 40% of adults aged 30+, contribute significantly to chronic low-grade systemic inflammation. Haematogenous dissemination of periodontal pathogens and continuous release of pro-inflammatory cytokines alter endothelial function, promote atherosclerosis, and increase overall cardiovascular risk. Studies report that untreated chronic oral infections can triple the risk of developing coronary artery disease.

The Evolving Landscape: ESC 2024 and AHA/ACC 2025 Guidelines

The nosological and therapeutic framework for hypertension has been profoundly redefined by recent consensus publications from global cardiology bodies.

ESC/ESH 2024

Updated from the 2018 guidelines. Introduces a simplified BP classification and emphasises risk-driven strategies. Reinforces lifestyle modifications as first-line treatment: sodium intake below 2 g/day, aerobic and isometric exercise programmes, and alcohol limitation.

AHA/ACC 2025

Marks a decisive shift towards ultra-personalised medicine. Adopts the PREVENT risk calculator (replacing the old pooled cohort equations), integrating renal function, statin use, and social determinants of health. Lowers the 10-year CV risk threshold to 7.5% for Stage 1 pharmacological initiation — expanding eligible patients from 57% to 73%. Extends systematic screening for primary hyperaldosteronism to all Stage 2 or resistant hypertension.

Clinical Blood Pressure Classification

Diagnostic Category	Systolic (mmHg)		Diastolic (mmHg)
Normal	< 120	and	< 80
Elevated	120-129	and	< 80
Stage 1 Hypertension	130-139	or	80-89
Stage 2 Hypertension	≥ 140	or	≥ 90
Hypertensive Crisis	> 180	and/or	> 110-120

White Coat Effect and Masked Hypertension

White coat hypertension: abnormally elevated readings in the clinical setting (sympathetic hyperactivation from anticipatory anxiety), with normal ambulatory/home values. Masked hypertension: falsely reassuring in-office readings concealing pathological daily-life hypertension. Both carry a statistically higher risk of developing sustained hypertension with target organ damage. Discordant values warrant direct communication with the treating physician and prescribing of ambulatory BP monitoring (ABPM).

Screening Methodology and BP Measurement Protocols

The ADA formally stipulates systematic evaluation of vital signs — including pulse and blood pressure — at every visit for all adult patients. Incorrect posture, agitation, or inadequate measurement technique can generate artefactual readings, leading to misinterpretation and erroneous therapeutic decisions.

Standardised BP Measurement Protocol

1 Physiological rest: Patient seated in a quiet environment for a minimum of 5 minutes before measurement. Critical upon arrival to allow cardiovascular stabilisation after physical exertion or stress.

2 Positioning: Seated upright, back supported. Both feet flat on the floor (no leg crossing — alters venous return). Arm bared, relaxed, supported at exact heart level.

3 Validated equipment: Automatic oscillometric monitors preferred for reproducibility, subject to regular calibration. Cuff on the upper arm (biceps) only — wrist and finger devices are formally excluded. Bladder must cover 80% of arm circumference and 40% of width. Undersized cuff in obese patients causes clinically significant overestimation.

4 Validation by repetition: If initial reading is elevated, allow 5 additional minutes of relaxation, then remeasure. At first visit, measure both arms and retain the higher value as reference. Document arm used, patient position, and device type in the electronic health record.

Medical History and Pharmacological Enquiry

BP readings must be accompanied by an exhaustive history assessing the patient's functional reserve and physiological capacity to tolerate procedural stress. The interview must meticulously catalogue prescribed antihypertensives and, crucially, evaluate actual therapeutic compliance. A common anamnestic bias: patients whose hypertension is perfectly controlled by polytherapy may omit declaring themselves hypertensive, considering themselves "cured". The practitioner must also actively investigate signs of target organ damage (frequent dizziness, syncope, transient visual disturbances, nephropathy, signs of congestive heart failure such as exertional dyspnoea or orthopnoea, arrhythmia). The presence of any such marker radically alters the therapeutic approach and warrants immediate communication with the treating specialist.

Clinical Decision Thresholds for Dental Procedures

Safe management stratifies interventions by degree of urgency (elective vs emergency pain relief), cross-referenced with perioperative BP readings. The ADA and university hospital protocols define clear intervention thresholds to prevent acute decompensation in the chair.

BP Threshold (mmHg)	Elective Care Strategy	Emergency Care Strategy (Pain/Infection)
< 160 / 100	Proceed without major restriction. Periodic monitoring recommended.	Proceed without major restriction. Periodic monitoring recommended.
160-179 / 100-109	Defer. Medical consultation and clearance required before resuming.	Authorised with restrictions. Strictly palliative acts only. Continuous monitoring every 10-15 min. Full stress-reduction protocol.
≥ 180 / 110	Cancel. Immediate medical referral.	Cancel. Oral analgesics only. Transfer to hospital emergency if symptomatic.

Hypertensive Crisis (≥ 180/110 mmHg) — Absolute Contraindication

Regardless of the reason for consultation, absolutely no dental treatment may be undertaken. Any surgical or anaesthetic manipulation risks triggering a further hypertensive spike with potentially fatal consequences. The dentist's role becomes that of first medical responder: perform rapid neurological, cardiac and renal screening to differentiate a simple hypertensive urgency (no organ damage) from a true hypertensive emergency (target organ lesion). Fulminant headache, chest pain, dyspnoea, radiating dorsal pain, numbness, visual field alteration, or dysarthria signal a critical complication requiring immediate emergency medical services transfer.

Stress Physiology and Sedation Protocols

Dental anxiety and phobia powerfully activate the sympathetic nervous system, triggering a massive release of endogenous catecholamines (adrenaline, noradrenaline) from the adrenal medulla. This catecholaminergic surge induces elevated heart rate (positive chronotropy), increased myocardial contractility (positive inotropy), and intense peripheral vasoconstriction. In the hypertensive patient — whose vascular compliance is already compromised by chronic arterial stiffness and endothelial dysfunction — this sympathetic burst can transform a medically controlled BP into a perioperative hypertensive crisis with devastating consequences.

Non-Pharmacological Strategies

Scheduling and Ergonomics

Plan appointments preferably in the early morning. Patients are more rested and anxiety-generating waiting time is minimised. Keep sessions short to prevent the physical fatigue and psychological wear that lower pain tolerance thresholds.

Orthostatic Collapse Prevention

Most antihypertensives (alpha-blockers, ACE inhibitors, ARBs, diuretics, direct vasodilators) profoundly impair baroreflex compensatory mechanisms. Abrupt repositioning from supine to upright causes venous pooling in the lower limbs, precipitating a drastic fall in cerebral perfusion (orthostatic hypotension) leading to syncope or traumatic falls. Adopt gradual, staged repositioning at end of procedure; keep patient seated for several minutes before standing.

Pharmacological Sedation

Nitrous Oxide/Oxygen (N2O/O2) — First Choice

Nasal mask delivery of a 50:50 equimolar mixture. Rapid anxiolysis and mild amnesia within minutes. Significantly raises the nociceptive perception threshold. Provides continuous 50% oxygen supply, ensuring optimal myocardial oxygenation and preventing ischaemia under stress. Immediate reversibility upon cessation of inhalation confers an unmatched safety profile in general practice.

Oral / IV Benzodiazepine Sedation

Oral premedication (midazolam, diazepam, alprazolam) the evening before and 1 hour before the procedure breaks the anticipatory anxiety cycle. IV conscious sedation for complex surgery requires specific accreditation and continuous high-level monitoring (ECG, pulse oximetry, capnography, non-invasive BP) to manage respiratory depression risk.

Local Anaesthesia and Vasoconstrictors: The Physiological Debate

Absolute pain control is the keystone of hypertensive patient management. To achieve adequate depth, prolonged duration, and operative-field haemostasis, anaesthetic solutions (lidocaine, articaine) are systematically combined with a vasoconstrictor — universally, epinephrine (adrenaline).

The Clinical Paradox

Withholding vasoconstrictors to prevent the theoretical risk of systemic catecholamine absorption confronts the clinician with a far greater peril: analgesic failure. A non-adrenalinated anaesthetic dissipates rapidly due to the intrinsic vasodilatory properties of the anaesthetic molecule. If the patient experiences acute pain mid-procedure, the resulting panic and nociception trigger a massive endogenous catecholamine release whose blood concentrations far exceed those contained in one or two anaesthetic cartridges.

Modern Consensus

Acute pain constitutes a significantly greater cardiovascular danger than a judicious, slow, correctly aspirated injection of a micro-dose of exogenous epinephrine. The AHA and ADA jointly confirm that vasoconstrictors are not contraindicated in controlled hypertensive patients, provided strict dosage limits, slow injection velocity, and systematic iterative aspiration are observed.

Patient Profile	Max Epinephrine per Session	Cartridges (1:100,000)	Cartridges (1:200,000)
Healthy adult	0.20 mg	~11	~22
Hypertensive / CV disease (ASA III-IV)	0.04 mg	2 max	4 max

Contraindicated Practices

1:50,000 epinephrine formulations are strongly discouraged in this patient group. Epinephrine-impregnated gingival retraction cords are prohibited in uncontrolled hypertensives — the injured sulcular epithelium constitutes a rapid, uncontrollable systemic absorption route for sympathomimetic amines.

Non-Vasoconstrictor Alternatives

Mepivacaine 3% (Plain)

Formulated without any added vasoconstrictor. Provides short-to-medium duration anaesthesia suitable for simple procedures. More rapid tissue clearance than adrenalinated solutions.

Prilocaine + Felypressin

Prilocaine is intrinsically less cardiotoxic and produces less local vasodilation than lidocaine. Felypressin is a synthetic vasopressin analogue acting on V1 receptors of venous smooth muscle. It reduces blood flow without stimulating nodal tissue or the myocardium. It causes neither arrhythmia nor major hypertensive spike — the vasoconstrictor of choice in high-risk coronary or severely hypertensive patients.

Critical Drug Interactions with Antihypertensives

Hypertensive patients are enrolled in long-term, often complex polytherapy regimens. Commonly prescribed dental medications — analgesics, anti-inflammatories, antibiotics — carry a high potential for pharmacodynamic and pharmacokinetic interactions with antihypertensives. This risk is magnified in the elderly, whose hepatic metabolism and renal excretion are physiologically impaired.

NSAIDs: A Dangerous Antagonism

The interaction between NSAIDs (ibuprofen, naproxen, diclofenac, ketoprofen) and antihypertensives is one of the foremost concerns in daily dental practice. By inhibiting cyclooxygenases (COX-1 and COX-2), NSAIDs block the synthesis of vasodilatory prostaglandins (PGE2, PGI2) at the renal parenchyma. This reduces renal blood flow and glomerular filtration rate, inducing sodium and water retention. Co-prescription of NSAIDs exceeding 5 consecutive days can attenuate or entirely neutralise the hypotensive effect of ACE inhibitors, diuretics, and beta-blockers.

First-line Analgesic Recommendation

Paracetamol (acetaminophen) is the absolute first-choice molecule in the hypertensive patient, given its absence of effect on renal function and blood pressure. If an NSAID is indispensable for severe inflammation, prescribe at the lowest effective dose for no more than 3-5 days, with home BP monitoring advised.

Antibiotics and CYP450 Inhibition

Certain antibiotics — particularly macrolides (clarithromycin, erythromycin) and imidazoles (metronidazole) — act as potent inhibitors of hepatic cytochrome P450, specifically CYP3A4. The clinical concern: dihydropyridine calcium channel blockers (amlodipine, nifedipine, felodipine) are almost exclusively metabolised via CYP3A4. Concurrent macrolide prescription blocks this metabolic pathway, causing an exponential and toxic rise in antihypertensive plasma concentrations — uncontrolled peripheral vasodilation, severe hypotension, cardiogenic shock risk, and acute renal ischaemia.

Non-Selective Beta-Blockers and Epinephrine

Non-selective beta-blockers (propranolol, nadolol, timolol) block both beta-1 (myocardial) and beta-2 (peripheral vascular smooth muscle) receptors. When epinephrine is administered, its compensatory vasodilatory effect on beta-2 receptors is completely blocked. Epinephrine's action concentrates exclusively and massively on alpha-1 receptors, causing paroxysmal systemic vasoconstriction, a fulminant hypertensive crisis, followed by severe reflex bradycardia (vagal response) potentially progressing to cardiac arrest.

Dental Drug Class	Antihypertensive Involved	Mechanism	Clinical Consequence	Recommendation
NSAIDs	ACE inhibitors, ARBs, diuretics, beta-blockers	COX inhibition; renal prostaglandin blockade; sodium retention	Reduction/abolition of antihypertensive effect. BP rise. Renal insufficiency risk.	Prefer paracetamol. NSAIDs < 3-5 days if essential.
Macrolides (clarithromycin, erythromycin)	Calcium channel blockers (amlodipine, nifedipine)	Potent CYP3A4 inhibition	Toxic CCB plasma levels. Severe hypotension. Shock and renal ischaemia risk.	Check drug references. Substitute antibiotic if possible.
Epinephrine (anaesthetic cartridge)	Non-selective beta-blockers (propranolol, nadolol)	Beta-2 blockade; unopposed alpha-1 stimulation	Fulminant hypertensive crisis with severe reflex bradycardia.	Micro-doses only. Prefer vasoconstrictor-free alternatives (prilocaine, mepivacaine).

Complex Procedures in the Hypertensive Patient: The Endodontic Complication Model

The theory of hypertensive patient management finds its most critical application during complex, unplanned interventions that drastically prolong mouth-opening time and generate intense physiological and psychological stress. A paradigm illustrating this scenario: the iatrogenic fracture of a rotary NiTi endodontic file within the root canal (incidence: 0.28-16.2%).

The Stress Cascade

The incident announcement, unexpected session prolongation, multiple radiographs, and prolonged use of shrill ultrasonic inserts create an acute stress environment for both operator and patient. In the hypertensive individual, this accumulation of stressors is the ideal substrate for an endogenous adrenaline discharge leading to a dangerous hypertensive spike.

The Risk-Benefit Calculus

An ultrasonic retrieval attempt in the apical third of a molar can extend beyond 60-90 minutes. In a Stage 2 hypertensive patient, the physiological stress may generate a severe hypertensive spike far outweighing the theoretical benefits of file retrieval. The clinician must know when to change tactics: favour bypassing, or accept residual fragment inclusion (91.8% survival in non-infected canals) — the most enlightened medical decision for systemic patient preservation.

Meta-Analysis 2025 — Active Management Success

Active management (bypass or retrieval) yields a pooled Odds Ratio of 20.39 [95% CI: 2.68-155.18] in favour of intervention. Clinical success rates range from 68.1% to 95% depending on case complexity. However, in the hypertensive patient, the clinician must subordinate the pursuit of mechanical perfection to immediate haemodynamic safety.

Emergency Management of Hypertensive Crises in the Dental Chair

Despite all prophylactic precautions, an acute hypertensive episode during a dental procedure remains a medical emergency that every practice must be prepared to confront. The critical diagnostic challenge: distinguishing a benign BP elevation (simple urgency) from a true hypertensive emergency.

Hypertensive Emergency (Target Organ Damage)

Red-Flag Assessment (Seconds)

1 Neurological axis: Sudden fulminant headache, altered consciousness/confusion, transient motor deficits (limb weakness), visual field changes, dysarthria → impending stroke or hypertensive encephalopathy.

2 Cardiovascular/renal axis: Intense chest pain radiating to the back, severe dyspnoea, oxygen desaturation → acute pulmonary oedema, severe coronary insufficiency, or aortic dissection.

3 Action: Immediately call emergency medical services. High-flow oxygen (9-15 L/min). Do NOT attempt oral BP reduction — abrupt perfusion pressure drop could catastrophically worsen cerebral or myocardial ischaemia already in progress.

Simple Hypertensive Urgency (No Organ Damage)

If BP reads 185/115 mmHg but the patient reports only mild neurosensory symptoms (dull headache, floaters/phosphenes, nosebleed) or is simply extremely anxious with no focal signs of organ damage, it is a simple urgency.

First Response

Rest and Observation

Place patient semi-upright in a calm environment, isolated from cabinet noise and bright lights. Often sufficient to return BP to safe zones within 15-30 minutes, confirming the purely emotional nature of the spike.

If Medication Required

Target: -20% SBP in 1 Hour

Goal: reduce systolic by ~20% over the first hour and bring diastolic below 105 mmHg. NOT to achieve 120/80 in minutes. Nicardipine 20 mg or urapidil 60 mg orally (onset 15-20 min). Sublingual captopril 25 mg (onset 15-30 min, bypasses hepatic first-pass — confirmed by 2025 systematic review).

Absolute Pharmacological Contraindication

Sublingual nifedipine (Adalate 10 mg) is formally banned from emergency protocols. It triggers such fulminant and uncontrollable vasodilation that the brutal BP drop precipitates myocardial infarction or ischaemic stroke — transforming a manageable episode into a lethal iatrogenic catastrophe.

Associated Cardiovascular Pathology: The Infective Endocarditis Paradigm

Chronic hypertension induces inevitable myocardial remodelling (left ventricular hypertrophy) and loss of vascular compliance. The hypertensive patient presenting at the dental practice is very frequently carrying invisible vascular comorbidities: asymptomatic coronary disease, TIA history, early-stage chronic kidney disease, or valve pathology secondary to permanent haemodynamic stress.

Long-term antihypertensive therapies also produce oral cavity manifestations: pronounced xerostomia (diuretics), gingival tissue hyperplasia (calcium channel blockers such as nifedipine), and inflammatory oral lichenoid reactions (beta-blockers, ACE inhibitors).

Infective Endocarditis Prophylaxis (HAS/SFCO 2024 Update)

For high-IE-risk patients (prosthetic valve, IE history, complex congenital heart disease), oral manipulation exposes the bloodstream to massive transient bacteraemias capable of colonising the endocardium or valvular implants.

Absolutely Contraindicated Procedures

Direct/indirect pulp capping on mature permanent teeth. Pulpectomy of primary teeth. Any periodontal or implant surgery using guided bone regeneration membranes. All curative peri-implantitis treatment protocols.

Authorised Under Antibiotic Shield

Full endodontic treatment (mono- and multi-rooted teeth, except non-restorable teeth). Deep scaling. Simple extractions. Require single-dose prophylaxis: amoxicillin 2 g (or clindamycin 600 mg / azithromycin if penicillin-allergic) ingested 1 hour before the invasive procedure.

Intraligamentary and Osteocentral Anaesthesia — Second-Line Only

These techniques inject anaesthetic directly into the periodontal space or cancellous bone under high pressure, generating one of the densest bacteraemias in dentistry. HAS guidelines stipulate they should only be considered as a strict second-line option when all other loco-regional anaesthesia modalities have failed, to limit massive oral streptococcal inoculation in the vulnerable cardiac patient.

Frequently Asked Questions

Yes. This falls below the 160/100 mmHg threshold. Both elective and emergency dental care can proceed without major restriction, though periodic BP monitoring throughout the procedure and at the end of the appointment is strongly recommended. If the patient is not already known to be hypertensive, refer to their physician for assessment after the dental visit.

NSAIDs (including ibuprofen) inhibit renal prostaglandin synthesis, causing sodium and water retention. This can attenuate or completely neutralise the effect of ACE inhibitors, ARBs, diuretics, and beta-blockers within as little as 5 days of co-administration. Paracetamol has no effect on renal function or BP and is therefore the first-line analgesic of choice.

Yes, within strict limits. The AHA/ADA limit for cardiovascular patients is 0.04 mg per session (2 cartridges at 1:100,000 or 4 at 1:200,000). Slow injection with systematic aspiration is mandatory. The physiological data are clear: endogenous catecholamine levels from pain-induced stress far exceed the exogenous dose in standard cartridges. Inadequate analgesia is the greater cardiovascular danger.

Orthostatic hypotension. Most antihypertensives (alpha-blockers, ACE inhibitors, ARBs, diuretics) impair baroreflex compensation. Abrupt repositioning from supine to upright causes venous pooling in the lower limbs and a sudden drop in cerebral perfusion, potentially leading to syncope or traumatic falls. Always raise the chair gradually, in stages, and keep the patient seated for several minutes before standing.

Sublingual nifedipine causes such rapid and uncontrollable vasodilation that the resulting abrupt BP drop triggers ischaemia of vital tissues — precipitating myocardial infarction or ischaemic stroke. It transforms a manageable hypertensive urgency into a lethal iatrogenic event. Sublingual captopril (25 mg, onset 15-30 min) is the validated alternative with a controllable, predictable antihypertensive effect.

Conclusion. Dental management of the hypertensive patient demands a genuine posture of orofacial physician, orchestrating a holistic, preventive, and personalised approach. The 2024 ESC and 2025 AHA/ACC guidelines redefine diagnostic paradigms with global risk calculators and expanded treatment eligibility, reaffirming the dental practice's strategic frontline position in cardiovascular screening.

Clinical safety rests on meticulous history-taking (countering white coat effects, non-compliance, and masked hypertension), an unimpeachable BP measurement protocol, and strict adherence to decision thresholds: proceed below 160/100, defer elective care above, and formally prohibit all treatment with emergency transfer above 180/110. Mastery of the pain-control triad — environmental or pharmacological sedation (N2O/O2, benzodiazepines) to neutralise psychological stress, precisely dosed epinephrine (capped at 0.04 mg) to prevent explosive endogenous catecholamine release, and the strictest vigilance over postoperative drug interactions (NSAIDs, macrolides, beta-blocker/epinephrine conflict) — forms the cornerstone of safe practice.

Finally, the art of care reveals itself most acutely when the clinician faces the unforeseen. In the hypertensive patient undergoing complex endodontic complications, the practitioner must subordinate the pursuit of mechanical radicular perfection to the immediate haemodynamic safety of the individual — knowing that a well-conducted bypass is always preferable to a retrieval at the cost of a cardiac crisis.

References

1. OUHSC College of Dentistry — Guidelines for Hypertension Patients 2025-2026. codclinicoperations.ouhsc.edu guideline

2. Maryland Dept. of Health — Dental Management for the Hypertensive Patient. health.maryland.gov guideline

3. AHA — Ready, Set, Go! Quick Guide to Blood Pressure. heart.org guideline

4. ADA — Hypertension. ada.org guideline

5. ESC — 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. escardio.org guideline

6. PMC — Updates in the 2025 AHA/ACC Hypertension Guideline. pmc.ncbi.nlm.nih.gov guideline

7. AHA Journals — 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for High Blood Pressure in Adults. ahajournals.org guideline

8. PMC — Key Updates to the 2024 ESC Hypertension Guidelines and Future Perspectives. pmc.ncbi.nlm.nih.gov review

9. NephJC — PREVENT, Detect, Treat: What's New in the 2025 Hypertension Toolkit. nephjc.com review

10. Epic Research — 2025 Guideline Update Expands Stage 1 Treatment Eligibility from 57% to 73%. epicresearch.org review

11. Pharmacy Times — New 2025 Hypertension Management Guidelines Include Key Updates. pharmacytimes.com review

12. PMC — Interdisciplinary Management of White Coat Hypertension in Geriatric Oral Surgery. pmc.ncbi.nlm.nih.gov review

13. RCDSO — Dental Management of the Adult Hypertensive Patient. fr.rcdso.org guideline

14. UFSBD — MEOPA Conscious Sedation in the Dental Office. ufsbd.fr guideline

15. ADA — Guidelines for the Use of Sedation and General Anesthesia by Dentists. ada.org guideline

16. MDPI / PMC — Pharmacological Interactions of Epinephrine at Concentrations Used in Dental Anesthesiology: An Updated Narrative Review. mdpi.com review

17. PMC — Clinical assessment of the safe use of local anaesthesia with vasoconstrictor agents in cardiovascular compromised patients: A systematic review. pmc.ncbi.nlm.nih.gov meta

18. PMC — How safe is therapeutic dose of lignocaine with epinephrine: An overview. pmc.ncbi.nlm.nih.gov review

19. StatPearls / NCBI — Maximum dosage for anesthetic solutions commonly used in dentistry. ncbi.nlm.nih.gov review

20. ESH Online — Interactions Between Antihypertensive Agents and Other Drugs. eshonline.org review

21. FOMM — An update on drug interactions involving anti-inflammatory and analgesic medications in oral and maxillofacial medicine. fomm.amegroups.org review

22. PMC — Unveiling Drug-Drug Interactions in Dental Patients: A Retrospective Real-World Study. pmc.ncbi.nlm.nih.gov review

23. Medicina Oral — Interactions between ibuprofen and antihypertensive drugs: Incidence and clinical relevance in dental practice. medicinaoral.com review

24. ANSM — Thesaurus des Interactions Medicamenteuses. ansm.sante.fr guideline

25. ResearchGate — Success Outcomes for Bypass or Retrieval of Fractured Endodontic Instruments: A Systematic Review (2025). researchgate.net meta

26. UFSBD — Emergency Kit for the Dental Practice. ufsbd.fr guideline

27. ResearchGate — Sublingual vs. Oral Captopril in Hypertensive Crisis (2025 systematic review). researchgate.net meta

28. HAS — Prise en charge bucco-dentaire des patients a haut risque d'endocardite infectieuse (2024 update). has-sante.fr guideline

29. SFPIO — Actualisation des recommandations de prise en charge des patients a risque d'endocardite infectieuse. sfpio.com guideline

30. Dentibiotic — Nouvelles Recommandations HAS pour les patients a haut risque d'endocardite infectieuse. dentibiotic.fr local

Disclaimer

This article has been produced for informational and continuing education purposes only. It does not constitute personalised clinical or medical advice. Blood pressure thresholds, drug dosages, and protocol recommendations cited are drawn from the referenced international guidelines and peer-reviewed literature available at the time of writing and may be subject to revision. Clinicians should exercise independent professional judgement, consult primary literature (ESC 2024, AHA/ACC 2025, HAS/SFCO 2024, ANSM Thesaurus), and refer to local regulatory frameworks before applying any protocol described herein. Specific product mentions do not imply endorsement.